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Jeffrey A. Rappaport and Scott A. Waldman*
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States
Guanylate cyclase C (GUCY2C) is a transmembrane receptor expressed on the
luminal aspect of the intestinal epithelium. Its ligands include bacterial heat-stable
enterotoxins responsible for traveler’s diarrhea, the endogenous peptide hormones
uroguanylin and guanylin, and the synthetic agents, linaclotide, plecanatide, and
dolcanatide. Ligand-activated GUCY2C catalyzes the synthesis of intracellular cyclic
GMP (cGMP), initiating signaling cascades underlying homeostasis of the intestinal
epithelium. Mouse models of GUCY2C ablation, and recently, human populations
harboring GUCY2C mutations, have revealed the diverse contributions of this signaling
axis to epithelial health, including regulating fluid secretion, microbiome composition,
intestinal barrier integrity, epithelial renewal, cell cycle progression, responses to DNA
damage, epithelial-mesenchymal cross-talk, cell migration, and cellular metabolic status.
Because of these wide-ranging roles, dysregulation of the GUCY2C-cGMP signaling
axis has been implicated in the pathogenesis of bowel transit disorders, inflammatory
bowel disease, and colorectal cancer. This review explores the current understanding
of cGMP signaling in the intestinal epithelium and mechanisms by which it opposes
intestinal injury. Particular focus will be applied to its emerging role in tumor suppression.
In colorectal tumors, endogenous GUCY2C ligand expression is lost by a yet undefined
mechanism conserved in mice and humans. Further, reconstitution of GUCY2C signaling
through genetic or oral ligand replacement opposes tumorigenesis in mice. Taken
together, these findings suggest an intriguing hypothesis that colorectal cancer arises
in a microenvironment of functional GUCY2C inactivation, which can be repaired by oral
ligand replacement. Hence, the GUCY2C signaling axis represents a novel therapeutic
target for preventing colorectal cancer.
Keywords: guanylate cyclase C, cGMP, intestinal epithelium, colorectal cancer, microbiome, DNA repair,
inflammation, cancer prevention
INTRODUCTION
Constituting the largest interface with non-sterile material from the outside world, the intestinal
epithelium regulates fluid and nutrient transport, hosts commensal flora, and protects against
infiltration by toxins and pathogenic organisms that pass through the digestive tract (1). These
functions are accomplished by a single-cell layer of columnar epithelial cells, which form a
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mechanical barrier dividing the systemic compartment from the
turbulent gut lumen. Insults from the lumen induce continuous
epithelial cell turnover, requiring tremendous regenerative
capacity, with as many as 1011 gut epithelial cells replaced each
day (2). This proliferative status predisposes the epithelium to
neoplastic transformation, arising from corruption of circuits
that normally maintain epithelial homeostasis.
The healthy epithelium exhibits a highly organized structure
(Figure 1). Epithelial cells are polarized such that their apical
surface faces the intestinal lumen, engaging in nutrient
absorption and fluid secretion. The basolateral surface rests
on a basement membrane and interfaces with the supportive
stroma, vasculature, and mesenchymal cells of the underlying
lamina propria. A network of junctional complexes stiches
adjacent epithelial cells together, restricting paracellular transport
between the mucosal surface, and subepithelial tissue (3). To
increase absorptive surface area, the small intestinal epithelium
is organized vertically with invaginations into the mucosa, called
crypts, and projections into the lumen, called villi. In contrast, the
surface of the large intestine is relatively smooth (lacking villi),
with deep mucus-secreting crypts, enabling fluid absorption and
stool transit.
This crypt-villus axis is a physiologically unique structure,
characterized by continuous cell proliferation and turnover. At
the base of the crypt, long-lived stem cells give rise to rapidly
proliferating daughter cells, which differentiate into specialized
epithelial cell subtypes (4). These cells migrate upwards from
crypt to villus, differentiating into nutrient-absorbing enterocytes
(the majority of the epithelial population), mucus-secreting
goblet cells, and hormone secreting enteroendocrine cells (2).
Another cell type, Paneth cells, migrate downward into the crypt,
where they nourish the stem cells and secrete antimicrobial
compounds into the lumen (5, 6). Terminally differentiated villus
cells persist only 3–5 days, over which time they migrate to the
tip of the villus, undergo apoptosis, and slough off into the fecal
stream (2).
Tight homeostatic control of the circuits regulating cell
division, differentiation, migration, and apoptosis, are critical
to maintain the barrier integrity, secretory, and absorptive
activity of the intestinal mucosa. The intestinal epithelial
receptor, guanylate cyclase C (GUCY2C), and its cyclic
nucleotide second messenger, cyclic guanosine monophosphate
(cGMP), play a critical role in the maintenance of mucosal
homeostasis, with GUCY2C being considered an emerging
guardian of intestinal integrity. Identified nearly 30 years ago
as a signaling network hijacked by diarrheagenic bacteria
to stimulate intestinal secretion (7), cGMP signaling in the
intestine is now recognized to underlie many homeostatic
functions required for epithelial health. As such, dysregulation
of cGMP signaling contributes to intestinal diseases including
bowel transit disorders, inflammatory bowel disease, and cancer
(8–11). We will briefly discuss the key players responsible
for the generation, effector function, and degradation of
cGMP in the intestine, followed by their contribution to
intestinal physiology and disease. Finally, we will conclude
with current approaches to targeting this axis for cancer
prevention.
FIGURE 1 | The intestinal crypt-villus axis. The small intestinal epithelium is
organized into villus projections into the gut lumen and crypt invaginations into
the lamina propria. Stem cells at the base of the crypt produce proliferative
daughter cells that give rise to differentiated cells of the villus. Epithelial cells
migrate from the proliferating compartment toward the tip of the villus where
they undergo apoptosis.
COMPONENTS OF THE INTESTINAL
CGMP SIGNALING AXIS
Guanylate cyclases are a ubiquitous class of enzymes that
catalyze the cyclization of the purine nucleotide guanosine
triphosphate (GTP) to the second messenger, cGMP (12, 13).
They are broadly classified by intracellular localization, residing
in either the particulate (membrane-bound) or soluble (cytosolic)
fractions of the cell. Depending on the isoform, guanylate
cyclases are activated by an array of signals including peptide
ligands, Ca2+ transients, and nitric oxide. In turn, cGMP
effectors include cGMP-dependent protein kinases (PKGs),
cGMP-gated ion channels, and phosphodiesterases (PDEs). The
spatiotemporal parameters of intracellular cGMP transients are
a function of synthesis by guanylate cyclases and degradation by
phosphodiesterases. In the spirit of brevity, we refer readers to
thorough reviews of guanylate cyclase signaling (12, 14). Here, we
will focus on the key elements of cGMP signaling in the intestinal
epithelium and their canonical role in fluid secretion (Figure 2).
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FIGURE 2 | The GUCY2C-cGMP signaling axis and intestinal fluid secretion. Activation of the receptor GUCY2C by its ligands increases intracellular cGMP levels. The
cGMP effector, PKGII, inhibits sodium ion absorption by the NHE3 transporter, and promotes anion secretion by the CFTR transporter, producing an electrolyte and
fluid gradient into the gut lumen. Through inhibition of the dual-specificity phosphodiesterases, PDE3, cGMP accumulation also cross-activates cAMP/PKA signaling,
which further potentiates CFTR. ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; CFTR, cystic fibrosis transmembrane conductance regulator;
cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; GUCY2C, guanylate cyclase C; NHE3, Na+/H+ exchanger III; PDE3, phosphodiesterases III;
PKA, protein kinase A; PKGII, protein kinase G II; ST, bacterial heat-stable enterotoxin; 5′-AMP, 5′-adenosine monophosphate; 5′-GMP, 5′-guanosine
monophosphate.
Guanylate Cyclase C (GUCY2C)
The GUCY2C isoform belongs to the particulate family of
guanylate cyclases. While other cyclases (including soluble
guanylate cyclase and the particulate guanylate cyclases A
and B) have a widespread tissue distribution, GUCY2C is
largely restricted to the intestinal tract (15, 16). It is expressed
as a homodimer on the apical brush border of intestinal
epithelial cells from the duodenum to the rectum, with
its ligand-binding extracellular domain facing the intestinal
lumen and its intracellular catalytic domain facing the cytosol
(12, 14). GUCY2C was initially characterized as the receptor
for the bacterial heat-stable enterotoxin, ST, the causative
agent of traveler’s diarrhea (7, 17). Extracellular ST binding
activates the catalytic domain, generating intracellular cGMP. In
turn, cGMP signaling canonically drives phosphorylation and
translocation of the cystic fibrosis transmembrane conductance
regulator (CFTR) to the cell surface, triggering Cl− and HCO−3
eﬄux into the intestinal lumen (18–20). Additionally, cGMP
signaling inhibits the apical Na+/H+ exchanger 3 (NHE3),
preventing Na+ absorption from the lumen (18–20). The
combined electrolyte eﬄux and retention in the lumen produces
an osmotic gradient that drives fluid secretion and, in the
pathological scenario, secretory diarrhea. Given this secretory
function, GUCY2C has emerged as an attractive target for the
treatment of constipation syndromes (21, 22). Two GUCY2C
agonists recently received FDA-approval for the treatment of
chronic idiopathic constipation and constipation-predominant
irritable bowel syndrome: linaclotide (LinzessTM) (23–25) an ST
analog, and plecanatide (TrulanceTM) (26, 27) an analog of the
endogenous GUYC2C ligand, uroguanylin (discussed below).
Efficacy and tolerability of these agents was recently summarized
(28).
GUCY2C Ligands
Ligands of GUCY2C include the aforementioned ST, of bacterial
origin, and the two endogenous peptides, uroguanylin and
guanylin, secreted by the epithelium of the human small and large
bowel, respectively (Figure 3) (29, 30). Two additional guanylin
species of non-human origin, lymphoguanylin and renoguanylin,
have been isolated from the American opossum (D. virginiana)
and the European eel (A. japonica), respectively (31–33). The
human intestinal guanylins are synthesized as propeptides by
epithelial cells of secretory lineages (34–37), and processed to
their mature, biologically-active, 16-mer (uroguanylin), or 15-
mer (guanylin) forms. The propeptide sequence is thought
to shield the site of ligand receptor interaction, although a
precise role for the pro-sequence and the steps in peptide
maturation remains unresolved (38). Structurally, these peptides
are characterized by disulfide bridges (three for ST and
two for the guanylins), which confer stability and resistance
to denaturation (hence the name “heat-stable” enterotoxin)
(14, 39, 40). Although the peptides share a high degree of
sequence similarity, uroguanylin is more potent at acidic pH. In
uroguanylin, two N-terminal aspartic acid residues were shown
to act as an acidic switch, altering the protein conformation
and enhancing ligand-receptor affinity 100-fold at pH 5 vs. pH
8 (40, 41). However, recent molecular dynamics simulations of
lymphoguanylin suggest that the hydrophobic core, rather than
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FIGURE 3 | GUCY2C Ligands. The four members of the guanylin protein
family are guanylin and uroguanylin, found in humans, and renoguanylin and
lymphoguanylin, found in other species. While the first three have a structural
conformation characterized by two disulfide bonds (yellow), lymphoguanylin
lacks the C-terminal cysteine (green), and therefore has only one disulfide
bond. A mutant guanylin (C115Y) similarly has only one disulfide bond and
lower potency of GUCY2C activation. In contrast, bacterial ST is characterized
by a rigid structure with three disulfide bonds. Synthetic GUCY2C agonists
include plecanatide and dolcanatide (uroguanylin analogs), and linaclotide (ST
analog). Amino acid differences between these analogs and the parent
compound are shown in red.
the acidic N-terminal residues, controls peptide conformation
(42). Despite our evolving understanding of the molecular
behavior of these peptides, it is clear that differences in pH
sensitivity of the ligands parallel their expression profiles along
the intestinal axis, with uroguanylin expressed in the acidic
environment of the duodenum, and guanylin expressed in the
neutral environment of the colorectum (22).
Guanylin peptides have gained increasing attention as drug
templates for the treatment of gastrointestinal disorders. In
addition to the aforementioned linaclotide and plecanatide, both
already FDA-approved, a second uroguanylin analog, dolcanatide
has shown promise in ameliorating intestinal inflammation
in rodent models (43, 44). From a production perspective,
guanylin peptide analogs can be challenging to synthesize
due to the presence of multiple cysteine bonds. Interestingly,
lymphoguanylin and a recently-identifiedmutant form of human
guanylin (C115Y) harbor a C-terminal tyrosine residue in place
of the typical cysteine, eliminating one disulfide bridge in
these species and lowering their potency to activate GUCY2C
(Figure 3) (45). Recent single nucleotide polymorphism and
structural analyses of guanylin peptide variants have lent insights
into features that can be exploited to develop new compounds in
this growing class of pharmaceutics (42, 45, 46).
cGMP-Dependent Protein Kinases
The primary effectors of cGMP are the cGMP-dependent
protein kinases (PKGs), PKGI, and PKGII. PKGs belong
to the serine/threonine class of protein kinases and consist
of three domains: (1) an N-terminal domain necessary for
homodimerization, autoinhibition, and subcellular localization,
(2) a regulatory domain consisting of two cGMP binding pockets,
and (3) a catalytic domain containing the ATP and substrate-
binding pockets (47). cGMP binding drives a conformation
change that releases the catalytic domain from the inhibitory N-
terminal domain, enabling kinase activity. Both PKG isoforms
are expressed in tissues throughout the body, including the
intestine. PKGI is present in smooth muscle cells, where
it regulates intestinal contractility (48), while PKGII is the
predominant cGMP effector in the intestinal epithelium, where
it regulates luminal fluid secretion (47, 49, 50). Tethered to the
apical plasma membrane, cGMP-activated PKGII canonically
phosphorylates CFTR andNHE3 to promote fluid and electrolyte
eﬄux (51, 52).
Phosphodiesterases
The cyclic nucleotides cGMP and cAMP are degraded to 5′-GMP
and 5′-AMP by a family of enzymes called phosphodiesterases
(PDEs). Eleven PDEs have been identified, each with varying
tissue distribution, subcellular localization, and affinity for cGMP
and cAMP. For example, PDE-4,−7, and−8 have higher affinity
for cAMP, PDE-5,−6, and−9 for cGMP, and PDE-1,−2,−3,−10,
and−11 hydrolyze both (53–55). PDEs that are expressed by
the intestinal epithelium and contribute to cGMP hydrolysis
include PDE-1,−2,−3,−5,−9 (53, 56, 57), and recently PDE10
(58). The extent to which epithelial-expressed PDEs with
higher cAMP affinity [such as PDE4 (57)] modulate cGMP
signaling remains unclear. However, cAMP and cGMP effectors
converge on several physiological endpoints, including CFTR
phosphorylation and fluid secretion. cGMP elevation indirectly
potentiates cAMP effectors by occupying dual-specificity PDEs,
thereby slowing degradation of cAMP. Additionally, some PDEs
contain regulatory binding sites for cGMP that potentiate (PDE2
and 5) or inhibit (PDE3) cyclic nucleotide degradation. Hence,
PDEs contribute a level of complexity to cyclic nucleotide
signaling, particularly through cAMP-cGMP cross talk. These
interactions remain to be comprehensively evaluated in the
intestine, and are an area of significant interest.
CGMP SIGNALING AND INTESTINAL
HOMEOSTASIS
The most apparent role of cGMP signaling in the intestine can
be appreciated from human populations harboring mutations
in GUCY2C, resulting in hyper- or hypo-secretion syndromes.
In the recently described familial GUCY2C diarrhea syndrome
(FGDS), a single missense mutation in the catalytic domain of
GUCY2C produces hyperactivation of the receptor in response
to ligand (9, 59, 60). This rare autosomal dominant disorder
(initially reported in 32 members of a Norwegian family) is
clinically characterized by loose stools, inflammation resembling
irritable bowel disease with diarrhea (IBS-D), a doubling of
intestinal transit time, and elevated intestinal pH. GUCY2C-
deactivating mutations have also been reported, including
missense mutations in the ligand-binding and catalytic domains,
and nonsensemutations eliminating the catalytic domain entirely
(10, 61). These autosomal recessive disorders, reported in Bedoin
and Lebanese families, produce meconium ileus (neonatal
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intestinal obstruction) due to GUCY2C insensitivity to its
ligands, diminished epithelial cGMP, and diminished CFTR-
mediated intestinal secretion.
These findings in humans mimic secretory defects observed
in mice lacking components of the cGMP signaling axis. For
example, GUCY2C−/− (62, 63) and PKGII−/− mice (50) are
insensitive to ST-mediated intestinal fluid secretion. Guanylin
deficient mice also have altered colonic electrolyte transport
(64). Given the small population of humans harboring GUCY2C
mutations, knockout mice have proven invaluable to the
identification of the more subtle functions of cGMP in intestinal
homeostasis, to be described below.
cGMP, Epithelial Proliferation, and
Differentiation Along the Crypt-Villus Axis
Intestinal epithelial renewal requires a continuous supply
of new cells produced by proliferation in the crypt. This
renewal is regulated by a signaling cascade controlled by the
extracellular ligand, Wnt, and its downstream transcriptional
effector, β-catenin (65). In the differentiated villus, extracellular
Wnt expression is low. In this context, cytosolic β-catenin
enters a multi-protein complex stabilized by the scaffold
proteins, adenomatous polyposis coli (APC) and axin. There,
serine/threonine kinases, casein kinase 1a and glycogen synthase
kinase 3, phosphorylate β-catenin, marking it for poly-
ubiquitination by the β-TrCP E3 ubiquitin ligase and degradation
by the proteasome. The presence of extracellular Wnt blocks
this process. Wnt binds to its cell surface receptor, Frizzled, and
co-receptor, LRP, which recruit axin to the plasma membrane
to destabilize the destruction complex. This allows β-catenin
to accumulate, translocate to the nucleus, associate with the T-
cell factor (TCF) family of nuclear transcription factors, and
activate a transcriptional program driving proliferation (66–69).
Wnt hormones are secreted at the base of the intestinal crypt,
providing a local niche conducive to stem cell renewal and
epithelial proliferation (5, 65). The intestinal stem cell, identified
only 10 years ago as the LGR5+ crypt base columnar cell (4), gives
rise to daughter cells that populate the transit amplifying zone
of the crypt. As these cells proliferate, migrate up the crypt, and
leave the stem cell niche, Wnt tone diminishes and is replaced
by Hedgehog and bone morphogenic protein (BMP) cascades,
which support senescence and differentiation into the various
specialized cells of the mature villus (70–72).
The balance of signaling promoting and opposing intestinal
Wnt signaling is essential for life. Elimination ofWnt signaling in
mice through disruption of β-catenin, TCF, its downstream target
c-myc, or overexpression of the Wnt inhibitor dickkopf, results
in crypt loss and fatal intestinal damage (73–76). Conversely,
uncontrolled Wnt signaling underlies the majority of colorectal
cancers. Spontaneous mutations inactivating the tumor
suppressor, APC, or stabilizing oncogenic β-catenin represent
the most common (>80%) driving mutations of sporadic colon
cancer (77). APC is a prototypical tumor suppressor, where an
initial spontaneous mutation produces allelic heterozygosity
and cancer susceptibility. Loss of the remaining allele (loss of
heterozygosity) eliminates APC from the β-catenin destruction
complex, enabling uncontrolled β-catenin-driven transcription
and tumorigenesis. This paradigm is most dramatic in patients
with the hereditary cancer syndrome familial adenomatous
polyposis (FAP), who harbor a germline mutation in one allele
of APC and develop hundreds of adenomas throughout the
colorectum by age 40 (77). This effect is mimicked in the
widely-studied APCmin/+ mouse, the first mouse model of
intestinal cancer, which harbors a truncating germline mutation
in one allele of APC and develops multiple intestinal polyps
(78, 79).
cGMP signaling opposes intestinal proliferation and promotes
differentiation. Genetic elimination of GUCY2C, its ligand
guanylin, or the cGMP effector PKGII results in intestinal
crypt hyperplasia, characterized by increased crypt length and
expansion of the proliferating compartment of transit-amplifying
cells (measured by the number of PCNA and Ki67-positive
cells) (80–82). In turn, differentiated cells of the secretory
lineage, including goblet, Paneth, and enteroendocrine cells,
are lost (81, 82). Interestingly elimination of GUCY2C also
changes the stem cell compartment, producing endoplasmic
reticulum stress in the crypt and shifting the balance of stem
cells from canonical LGR5+ cells, to reserve BMI1+ cells,
which normally remain in a quiescent state and repopulate
the crypt upon injury (83). Corresponding with these changes,
silencing GUCY2C increases tumorigenesis in APCmin/+ mice
and mice exposed to the mutagens, azoxymethane or N-nitroso-
N-methylamine, reflecting loss of epithelial cGMP (84, 85).
These findings suggest that cGMP signaling opposes the
events required for transformation by restricting proliferation
and promoting differentiation along the crypt-villus axis.
Interestingly, the absence of cGMP signaling is insufficient
to induce tumorigenesis, but may instead create a selective
advantage for transformed cells to proliferate and develop
tumors.
Several studies demonstrate that cGMP opposes proliferation
by arresting the cell cycle. This was observed nearly two
decades ago in colorectal cancer cell lines treated with the
GUCY2C ligands, ST and uroguanylin, 8-Br-cGMP (a cell
permeable cGMP), or the PDE inhibitor, zaprinast (86).
Subsequently, inactivation of GUCY2C in mice was shown
to accelerate epithelial cell cycle progression, specifically by
releasing a block at the G1/S transition (81). These mice
over-express epithelial cell cycle drivers (e.g., pRb, CDK4,
cyclinD1, β-catenin) and under-express cell cycle suppressors
(e.g., p27) (87). In turn, cGMP elevating agents, including
ST, 8-Br-cGMP, and the PDE inhibitor, exisulind, increase
transcription of the cyclin dependent kinase inhibitors, p21 and
p27, which control this G1/S transition (85, 87, 88). PKGII-
mediated phosphorylation and activation of the transcription
factor, SP1, initiates transcription at the p21/p27 promoters
(88).
In addition to cell cycle arrest, cGMP signaling modulates
other pathways involved in cell proliferation (Figure 4). For
example, extracellular Ca2+ opposes proliferation through
activation of plasma membrane-bound calcium-sensing
receptors (CaRs), and entry through cyclic-nucleotide-gated
ion channels. Stimulation of GUCY2C with ST recruits
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FIGURE 4 | cGMP opposes cellular proliferation. cGMP elevating agents include GUCY2C agonists, PDE inhibitors, and cell-permeable 8-Br-cGMP. cGMP and its
effector, PKG, oppose intestinal epithelial cell proliferation by upregulating nuclear transcription of cell cycle inhibitors (p21 and p27) and by opposing pro-proliferative
transcription mediated by the β-catenin/TCF and Akt pathways. Further, cGMP recruits calcium-sensing G-protein coupled receptors (CaRs) to the plasma membrane
and directly activates cGMP-gated calcium channels (CNGs), promoting Ca2+-mediated cytostasis. Akt, protein kinase B; CaR, calcium-sensing receptor; cGMP,
cyclic guanosine monophosphate; CNG, cGMP-gated calcium channel; GTP, guanosine triphosphate; GUCY2C, guanylate cyclase C; p21, cyclin dependent kinase
inhibitor 1A; p27, cyclin-dependent kinase inhibitor 1B; PDE, phosphodiesterase; PKG, protein kinase G; PTEN, phosphatase, and tensin homolog; SP1, specificity
protein 1; TCF, T-cell factor; 5′-GMP, 5′-guanosine monophosphate; 8-Br-cGMP, 8-bromo-cGMP.
CaRs to the cell surface and activates cGMP-gated channels,
resulting in Ca2+-mediated cytostasis (89). In addition,
transcriptomic profiling of GUCY2C+/+ and GUCY2C−/−
mouse intestinal epithelia revealed activation of pro-
proliferative circuits downstream of the serine/threonine
kinase, AKT, including metabolic reprogramming to a
neoplastic, glycolytic phenotype (87). Reconstitution of
cGMP signaling mobilizes the phosphatase, PTEN, the canonical
inhibitor of AKT, reversing this phenotype (87). Reports
also suggest that cGMP directly opposes the proliferative
transcriptional program of β-catenin/TCF (90). cGMP
elevation through PDE5 and PDE10 inhibition reduced β-
catenin accumulation, nuclear translocation, and downstream
transcriptional activity by an unknown mechanism in multiple
cancer cell lines (91, 92). It has been proposed that PKGII
suppresses β-catenin/TCF transcription through activation
of cJun N-terminal kinase (JNK) and the downstream
forkhead box O transcription factor 4 (FOXO4) (93). In
this model, activated-FOXO4 binds and recruits β-catenin
to alternative DNA-binding sites, preventing its association
with TCF and reducing TCF-mediated transcriptional output.
However, it was later shown by the same group that PKGII
suppresses JNK in mice (94). Furthermore, although there
have been reports of TCF-independent recruitment of β-
catenin to DNA, including by the FOXO family, a recent
comprehensive analysis of β-catenin DNA-binding sites in
mouse intestinal crypts revealed that TCF family members
are universally required for β-catenin recruitment (95).
Hence, the mechanisms by which cGMP signaling opposes
proliferation remain debated and likely involve with several
pathways.
cGMP, Genetic Instability, and DNA
Damage Repair
The intestinal epithelium is continuously exposed to DNA
damaging agents. These include exogenous agents, such as
radiation, microorganisms, and mutagenic substances in the
lumen, as well as endogenous agents, such as reactive oxidative
species (ROS) generated by metabolically-active crypt cells (96).
Cells detect and respond to DNA damage by several mechanisms.
The best-characterized guardian of genomic integrity, p53,
activates a transcriptional program in response to DNA damage
(97). Canonically, this begins with transcription of p21 to
suspend the cell cycle and DNA replication, followed by
activation of genes encoding DNA repair machinery, or if
the damage is beyond repair, pro-apoptotic Bcl-2 proteins.
Genetic instability, the corruption of normal DNA repair
mechanisms and accumulation of mutations, is a hallmark of
cancer and plays a central role in colorectal tumor progression
(77, 98). Most sporadic colorectal tumors arise through a
specific series of mutations, termed the adenoma-carcinoma
sequence, beginning with APC, and followed by mutations in
tumor suppressors such as p53 (60–70%) or oncogenes such
as KRAS (40%) that enable transformation (77). Interestingly,
only 10% of preneoplastic lesions progress to carcinoma
over a 10 year period, as the accumulation of mutations
required for tumorigenesis is slow (77). Genetic instability
and disrupted damage sensing mechanisms accelerate the rate
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of mutation and provide a survival advantage to malignant
cells.
Loss of APC predisposes for colorectal cancer partly
because it suppresses oncogenic β-catenin/TCF-driven
transcription, but also because APC regulates DNA repair
and chromosomal stability (99, 100). APC shuttles between
the cytoplasm, where it regulates the β-catenin destruction
complex, and the nucleus, where it modulates the DNA base
excision repair, double strand break repair, and replication
fork dynamics (101–104). Furthermore, through interactions
with EB1, a microtubule-binding protein, APC associates
with the kinetochore in mitotic cells, regulating spindle
assembly, orientation, and chromosome segregation (105).
Cells harboring truncated APC mutants have defects in
chromosome segregation (106) and APCmin/+ mice exhibit
tetraploidy (107). Indeed, a recent report highlighted the central
importance of APC in intestinal tumor suppression using a
doxycycline-inducible APC shRNA, enabling toggling of wild
type APC. Elimination of APC in the context of p53 and
KRAS mutations produced tumors, but removal of the shRNA,
reconstituting APC in established tumors, rapidly reversed
transformation and restored normal crypt-villus architecture
(108).
cGMP signaling promotes DNA damage repair and opposes
chromosomal instability in healthy tissue and in the context
of APC defects. Elimination of GUCY2C from wild type
and APCmin/+ mice produces DNA double strand breaks
(quantified by the marker phospho-γH2AX) and DNA oxidation
(84, 109). This underlying environment of DNA damage
in the absence of cGMP signaling predisposes to further
accumulation of mutations. Indeed, tumors from APCmin/+
mice lacking GUCY2C have a higher frequency of APC
loss of heterozygosity than those with GUCY2C, reflecting
genomic instability (84). Although the mechanism has yet
to be fully defined, cGMP signaling contributes to genomic
stability at least in part through metabolic reprogramming
from glycolysis to oxidative phosphorylation (characteristic of
proliferating vs. quiescent cells), decreasing ROS production
and oxidative DNA damage in mice and cancer cell lines (87).
Interestingly, deletion of CDX2, the intestinal transcription
factor responsible for GUCY2C expression (110, 111), similarly
potentiates tumor burden, chromosomal aberrations, and APC
loss of heterozygosity (112). This reflects stimulation of
mTOR, a downstream effector of AKT (112). Furthermore,
it was recently reported that GUCY2C contributes to DNA
integrity in part through a mechanism mediated by p53
(113). Elimination of GUCY2C from mice increased, while
oral administration of the GUCY2C ligand, ST, reduced
radiation-induced gastrointestinal toxicity in mice. cGMP
signaling potentiated p53 activation in response to radiation
injury, reducing DNA double strand breaks, abnormal mitotic
orientation, and aneuploidy (characteristics of chromosomal
instability). In summary, cGMP signaling potentiates DNA
damage response mechanisms and promotes cellular quiescence,
reducing susceptibility to chromosomal instability underlying
tumor progression.
cGMP, Intestinal Inflammation, and
Epithelial Barrier Integrity
The intestinal epithelium serves as both a selective conduit and
a barrier between the luminal and systemic compartments.
Transport between these compartments occurs by the
transcellular route (via selective amino acid, electrolyte,
and other nutrient transporters on the apical and basolateral
surfaces of the enterocyte) or by the paracellular route, which
is regulated by junctional complexes that bind the lateral walls
of epithelial cells together (114). These junctional complexes
are divided into three categories: desmosomes, adherens
junctions, and tight junctions, the latter of which seals the
paracellular space and is responsible for selective transport
between cells. Numerous factors regulate junction complex
integrity, particularly regulators of the inflammatory response
(115–117). Endogenous anti-inflammatory cytokines, such
as interleukin-10 (IL-10), promote barrier integrity (118).
Others, such as tumor necrosis factor alpha (TNFα) and
interferon gamma (IFNγ), key mediators of inflammation,
increase barrier permeability through myosin light chain kinase
(MLCK)-mediated phosphorylation of myosin light chain
(MLC), leading to tight junction disassembly (119). Exogenous
factors, such as alcohol and pathogenic microorganisms, also
increase membrane permeability (114). Dysfunction of the
epithelial barrier contributes to the pathology of numerous
diseases, including inflammatory bowel disease (IBD), irritable
bowel syndrome (IBS), sepsis, and autoimmune disease like
celiac disease and type I diabetes (114, 117). Severe intestinal
inflammation, such as IBD, also increases colorectal cancer risk
(120).
Aside from the overt phenotype of intestinal secretory
dysfunction, individuals harboring mutations in GUCY2C suffer
from IBD (9, 10), suggesting that cGMP signaling regulates
intestinal inflammation. Indeed, elimination of GUCY2C from
mice produces an inflammatory phenotype associated with
increased circulating and epithelial cytokines (109, 121, 122).
In one study, intraperitoneal lipopolysaccharide injection (a
bacterial endotoxin that provokes the immune response),
produced greater proinflammatory gene expression (including
TNFα and IFNγ) in colonocytes of GUCY2C−/− relative
to wild type littermates (122). Additionally, elimination of
GUCY2C from the intestine of a genetic intestinal colitis model
(IL10−/−) accelerated the onset of the disease (122). This
suggests that homeostatic cGMP signaling reduces sensitivity to
inflammatory stimuli. For example, mice exposed to dextran-
sodium sulfate (DSS; a chemical model of intestinal inflammation
mimicking IBD) and treated with plecanatide (a GUCY2C
agonist) or sildenafil (a PDE5 inhibitor), were protected from
inflammation compared to untreated mice (43, 123, 124). This
effect was measured by epithelial histologic scoring, immune
cell recruitment, expression of inflammatory cytokines, and
inflammation-driven tumorigenesis (43, 123, 124).
cGMP signaling opposes intestinal inflammation at least
in part through protection of epithelial barrier integrity.
Elimination of GUCY2C in mice produces a phenotype of
increased intestinal permeability, driven by MLC-mediated tight
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junction disassembly and increased basal levels of epithelial
IFNγ, a canonical driver of intestinal permeability (121).
Subsequent transcriptomic profiling of GUCY2C−/− mouse
epithelium also revealed decreased expression of 74 tight junction
genes, including occludin, claudin-2, claudin-4, and JAM-
A, contributing to loss of barrier integrity and susceptibility
DSS-induced colitis (109). These changes were mediated by
aberrant AKT signaling, which is opposed by cGMP signaling.
A complementary mechanism was recently proposed, examining
the role of reactive oxygen species in disrupting barrier integrity.
Wang et al. suggest that cGMP signaling enhances barrier
integrity through activation of the transcription factor, FOXO3a
and its downstream antioxidant transcriptional targets (125).
FOXO3a is phosphorylated and inactivated by AKT. Treatment
of colon cancer cells, human biopsy specimens, and mice
with 8Br-cGMP or the PDE5 inhibitor, vardenafil, suppressed
AKT signaling, activated FOXO3a-mediated transcription of
antioxidant species, and enhanced barrier integrity in the DSS-
colitis model. These effects were abolished in PKGII−/− animals,
confirming the role of cGMP. Collectively, several laboratories
have confirmed that cGMP signaling promotes intestinal barrier
integrity and opposes intestinal inflammation. The extent to
which these effects are mediated changes in cytokine expression,
regulators of tight junction assembly, expression of junction
components, or potentiation of antioxidant species remains an
open-ended question.
cGMP and the Intestinal Microbiome
Beyond its role in regulating fluid transport and nutrient
absorption, the human intestine serves as a host for the
densest population of microorganisms in the body, over 1011
microbes/mL by intestinal volume (126). The gut microbiome
consists of over 1,000 species, varying in proportion from
individual to individual depending on age, diet, geographic
location, genetics, and other factors, which we have only
begun to dissect since in the advent of large scale sequencing
techniques (127, 128). Commensal bacteria, predominantly of
the bacteroidetes and firmicutes phyla, thrive in the nutrient-
rich environment provided by the intestinal epithelium. In turn,
they complement gaps in host metabolic pathways, such as the
fermentation of indigestible carbohydrates and synthesis of short
chain fatty acids, a key energy source and signaling molecule for
the epithelium (126, 128, 129). Beyondmetabolic commensalism,
gut bacteria defend against colonization by pathogenic species.
These bacterial defense mechanisms occur indirectly through
stimulation of the host immune response, and directly through
nutrient competition and release of bactericidal small molecules
(126, 130). For example, bacterial synthesis of short chain fatty
acids opposes infection by enteropathogenic E. coli and virulence
gene expression by S. Typhimurium in the colon (131, 132).
Alterations in diversity and composition of the intestinal
flora, termed dysbiosis, characterize several intestinal diseases,
including IBD and colorectal cancer. Whether these changes
are a cause or consequence of disease remains an active
area of research. However, mice treated with antibiotics,
or housed in germ-free environments, exhibit intestinal
mucus thinning, susceptibility to colitis, and acceleration
of tumorigenesis, indicating that bacterial factors play a
driving role (133–136). Chronic inflammation (e.g., IBD) is
a risk factor for colorectal cancer, and bacterial species may
contribute to tumorigenesis by producing an inflammatory
state. Enrichment of specific bacterial species in the intestines
of colorectal cancer patients, such as pro-inflammatory
Fusobacterium and Enterococcaceae, and loss of anti-
inflammatory butyrate-producing strains, such Roseburia
and F. prausnitzii, alter the epithelial microenvironment
and increase tumor susceptibility (137). Further, pro-
carcinogenic species, including strains of E. faecalis, and
E. coli, produce ROS and genotoxic virulence factors that
drive mutations underlying transformation (137). Indeed,
it was recently reported that patients with the hereditary
colon cancer syndrome, FAP, harbor patches of E. coli-, and
B. Fragilis-enriched biofilms, which are absent in normal
individuals (138). These species secrete the toxins colibactin
and B. fragilis toxin, respectively, which increase levels of
inflammatory cytokines, DNA damage, and tumor onset in mice
(138).
Epithelial cGMP has recently emerged as a regulator of
microbiome composition, particularly through modulation of
epithelial mucus properties. The colonic mucus is comprised two
layers – (1) a sterile inner layer, rich in secreted immunoglobulin
A and bioactive molecules (e.g., trefoil factor peptides, restin-like
molecule b), that protects the epithelium from direct bacterial
contact, and (2) an outer layer home to bacterial flora (126,
139). The mucus matrix is organized around the glycoprotein,
mucin 2, secreted by epithelial goblet cells, which provides
attachment sites and nutrition to commensal bacteria in the
outer layer (139). It has been hypothesized that cGMP-mediated
regulation of mucus hydration and pH through apical CFTR
and NHE3 channels regulates bacterial colonization of the
epithelial surface (140, 141). Indeed, elimination of GUCY2C
from mice alters the composition of bacterial flora detected
in the stool (140). Further, compromised barrier integrity in
these mice increased susceptibility to systemic dissemination of
the murine enteric pathogen, C. rodentium (140). Mice lacking
GUCY2C also were more susceptible to a bacterial species that
actively invades enterocytes, S. enterica, due to thinning of
the protective mucus layer (141). In turn, administration of a
GUCY2C agonist reduced bacterial adhesion and invasion. These
findings support the notion that cGMP-mediated modulation
of mucus hydration regulates bacterial colonization, and in
turn, the relative proportions of commensal vs. pathogenic
species.
cGMP signaling, microbiome composition, and colorectal
cancer intersect in the long-recognized inverse relationship
between colonization with diarrheagenic E. coli and incidence
of colorectal cancer. Geographic regions with endemic
enterotoxgenic E. coli (ETEC, responsible for Traveler’s diarrhea),
which produce the virulence factor and GUYC2C agonist, ST,
have far lower rates of colon cancer (142). ST stimulation of
GUCY2C arrests cell proliferation (86, 89, 142), suggesting an
intriguing hypothesis that chronic ETEC colonization confers
tumor resistance. Our group recently confirmed a role for
chronic ST-exposure in tumor prevention. Mice colonized
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for 18 weeks with ST-producing E. coli, mimicking chronic ST
exposure in endemic regions of the world, developed a 50% lower
tumor burden in response to the carcinogen, azoxymethane,
than mice colonized with ST-negative E. coli (143). This
finding reinforces the role of the GUCY2C-cGMP signaling
axis, as well as the role of microbiome composition, in tumor
susceptibility.
cGMP and Epithelial-Mesenchymal Cross
Talk
Intestinal development and homeostasis rely on reciprocal
signaling between the epithelium and underlying lamina
propria. Derived from embryonic mesoderm, the lamina
propria consists of acellular (extracellular matrix) and cellular
[fibroblasts, pericytes, stromal stem cells, smooth muscle cells;
(144)] elements that provide structural support and paracrine
cues to the epithelium. Mesenchymal cells regulate epithelial
proliferation and senescence, maintain and restrict the stem
cell niche, and remodel the extracellular matrix (145). Under
normal conditions, stromal fibroblasts remain in a quiescent
state, secreting extracellular matrix proteins, matrix-modulating
enzymes, and soluble growth and differentiation factors that
maintain the underlying stroma architecture and promote
epithelial differentiation. For example, fibroblasts surrounding
the crypt base secrete Wnt molecules (Wnt2b, 4, 5a, 5b) and
BMP antagonists (gremlin-1, gremlin-2, chordin-like 1) that have
receptors on the epithelium and drive proliferation in the crypt
(65, 146–148). They also restrict the stem cell niche in a vertical
gradient through secretion of BMPs and Wnt antagonists to
prevent β-catenin signaling outside of the normal proliferating
zone (65, 72, 146, 147, 149). Fibroblasts also respond to
epithelial injury (including mechanical stress, reactive oxidative
species, inflammatory cytokines, or growth factors), converting
to metabolically active myofibroblasts, which engage in matrix
remodeling necessary for wound repair (144, 147). The primary
stimulus driving the conversion of fibroblasts to myofibroblasts
is transforming growth factor beta (TGFβ), secreted by the
overlying epithelium. Resolution of injury repair and decline
of TGFβ secretion results in myofibroblast apoptosis and/or
reversion to a quiescent phenotype.
Pathological conditions, including chronic inflammation
and neoplastic transformation, promote the recruitment of
activated fibroblasts in a mutually reinforcing feedback loop.
Secretion of TGFβ by injured, inflamed, or neoplastic epithelium
activates fibroblasts, inducing changes in their proliferation,
migration, adhesion, secretory, andmatrix remodeling properties
(145, 150–152). In turn, activated fibroblasts produce a stromal
environment rich in extracellular matrix and secreted growth
factors that are conducive to tumor growth, termed desmoplasia.
Desmoplastic stroma has unique properties that promotes
tumor invasion and metastasis, including remodeling of
the normal Wnt and BMP gradients that define crypt
architecture (145, 153, 154). Cancer-associated fibroblasts also
directly promote tumorigenesis through the secretion of
inflammatory cytokines and growth factors, such as hepatocyte
growth factor (HGF), which is recognized by epithelial MET
proto-oncogene receptor tyrosine kinase (c-MET) and promotes
proliferation and invasion (145, 153).
cGMP signaling opposes epithelial-mesenchymal interactions
underlying tumorigenesis. Several studies have described
mechanisms by which intestinal cGMP signaling inhibits
cancer cell migration, invasion, and microenvironment
remodeling (155–159). cGMP suppresses the release of matrix
metalloproteinases (MMPs; enzymes that cleave extracellular
matrix components) by colon cancer cells, and was shown to
prevent metastatic seeding of these cancer cells in mice (156).
Further, loss of cGMP signaling in colon cancer cells promotes
the assembly of actin-based motility organelles (filopodea)
and invasion organelles (invadopodia) involved in tumor cell
migration (157). PKG-mediated phosphorylation of vasodilator-
stimulated protein (VASP), an actin-binding protein, opposes
this cytoskeletal remodeling (157). Finally, silencing GUCY2C in
mice and human cancer cells drives AKT-dependent secretion
of TGFβ by the epithelium, producing fibroblast activation and
a desmoplastic phenotype characteristic of early transformation
(158). In turn, activated fibroblasts secrete HGF, reciprocally
driving epithelial proliferation. Collectively, cGMP signaling
opposes matrix remodeling and a cellular-invasion phenotype.
Beyond its role as an intracellular second messenger,
cGMP also acts as a paracrine signaling molecule in the
intestine. Activation of GUCY2C produces intracellular cGMP
accumulation, as well as cGMP release into the extracellular
environment (160–162). This extrusion is mediated by the
membrane anion channel, multi-drug resistance protein 4
(MRP4), expressed on the apical and basolateral membranes
of the epithelium (162, 163). Extracellular cGMP promotes
analgesia by acting on visceral nociceptive neurons, and as such,
the GUCY2C signaling axis has been targeted for the treatment
of pain in constipation-predominant irritable bowel syndrome
(IBS-C) (160, 161, 164). Other roles for cGMP in the intestinal
stroma are unknown. It is tempting to speculate that given the
various tumor-suppressive roles of cGMP signaling, pathological
conditions that diminish extracellular cGMP could create a local
microenvironment susceptible to transformation. However, its
role as a paracrine tumor suppressor remains purely hypothetical
because a cGMP receptor or cGMP uptake transporter have yet to
be identified, and its extracellular mechanisms of action remain
elusive.
cGMP DYSREGULATION IN COLORECTAL
CANCER AND THERAPEUTIC
IMPLICATIONS
Colorectal cancer remains the second leading cause of cancer
death and fourth most incident cancer in the United States
(165). Genetic alterations underlying tumorigenesis have
been well defined; namely, the driving mutations in APC
and β-catenin, which lift a block on proliferation along the
crypt-villus axis (77). Furthermore, certain risk factors such
as chronic inflammation (i.e., IBD), smoking, and obesity
predispose patients to the development of tumors. Yet, the
underlying changes in the intestinal epithelial microenvironment
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FIGURE 5 | Suppression of cGMP signaling promotes epithelial transformation. Basal cGMP tone in the intestinal epithelium promotes epithelial homeostasis. cGMP,
through its effector, PKG, regulates several downstream mechanisms including mucus hydration, metabolism, inflammation, barrier integrity, DNA damage sensing,
and cell cycle progression. In contrast, intestinal transformation is characterized by upregulation of phosphodiesterases and suppression of GUCY2C paracrine
ligands, reducing intracellular cGMP and producing an epithelial phenotype predisposed to cancer progression. cGMP, cyclic guanosine monophosphate; GTP,
guanosine triphosphate; GUCY2C, guanylate cyclase C; HGF, hepatocyte growth factor; IFNγ interferon gamma; PDE, phosphodiesterase; PKG, protein kinase G;
TGFβ, transforming growth factor beta; TNFα tumor necrosis factor alpha; 5′-AMP, 5′-adenosine monophosphate; 5′-GMP, 5′-guanosine monophosphate.
that tip the homeostatic balance in favor of tumorigenesis
remain poorly understood. Genetic mutations represent an
irreversible phenomenon, and the standard of care remains
surgical and chemotherapeutic approaches to eliminate
transformed tissue. Hence, the identification of reversible
factors contributing to the earliest stages of transformation are
needed.
Cell-Autonomous Suppression of cGMP
Signaling in Colorectal Cancer
cGMP has emerged as a key regulator of intestinal circuits
that oppose tumorigenesis (Figure 5). As such, suppression of
cGMP signaling is a common thread in colorectal cancers
and may be necessary for tumorigenesis. Indeed, a recent
analysis of mRNA and long non-coding RNA expression in
tumor vs. normal tissue samples on the TCGA database
identified the PKG-cGMP pathway among the top regulated
gene networks (166). One mechanism of cGMP suppression
is altered intracellular expression of cGMP axis elements,
resulting in loss of cGMP signaling in cancer cells. For
example, upregulation of PDEs accelerates hydrolysis of cyclic
nucleotides. PDE5 elevation has been observed in human colon
cancer cell lines and tumor samples compared to normal
tissue, and PDE10 elevation has been observed in human
cell lines, biopsy specimens, and tumors from APCmin/+
mice (58, 90, 124, 167). Another study found that expression
of PDE4B (which preferentially degrades cAMP) was elevated
in histologically normal-appearing intestinal epithelium from
colorectal cancer patients, suggesting that cyclic nucleotide
TABLE 1 | PDE inhibitors shown to oppose tumorigenic cell circuits.
Specificity Functions Regulated Models
Sulindac sulfone
(Exisulind)
PDE5 Apoptosis, (181) cell
proliferation, (88) polyp
multiplicity (182–184)
cells, mice,
humans
Sulindac benzylamine PDE5 Cell proliferation and
apoptosis (167)
cells
Sulindac sulfide PDE5 Cell proliferation and
apoptosis (185)
cells
Sildenafil PDE5 Polyp multiplicity, (186)
colitis, (124)
inflammation-induced
polyps (124, 187)
mice
Vardenafil PDE5 Cell proliferation (94),
colitis (94), redox stress
(125)
cells, mice
Zaprinast PDE5, 6,
9, 11
Cell proliferation (86) cells
ADT-094 PDE5, 10 Cell proliferation (91) cells
Papaverine PDE10 Cell proliferation (58, 91) cells
PQ-10 PDE10 Cell proliferation (58) cells
Pf-2545920 PDE10 Cell proliferation (58, 92) cells
dysregulation occurs early in transformation, preceding other
histologic markers (57). Suppression of the cGMP effector, PKGI,
has also been observed in colon tumor specimens compared to
normal tissue, contributing to angiogenesis in tumor xenografts
(168, 169).
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Inhibition, rather than changes in expression of cGMP
signaling elements also contributes to silencing of the
signaling axis. C-src, a tyrosine kinase overexpressed
in colorectal cancer, phosphorylates tyrosine 820 on the
catalytic domain of GUCY2C, inhibiting receptor activation
(170). An alternative mechanism of receptor silencing may
involve removal from the cell surface and sequestration in
subcellular compartments, which was recently observed by
immunohistological staining of multiple gastrointestinal
malignancies (171). Whether changes in localization regulate
cGMP generation remains unknown. Hence, through various
mechanisms, silencing the tumor-suppressive properties of
cGMP signaling appears to be a common feature of colorectal
cancer.
GUCY2C Paracrine Hormone Loss in
Colorectal Cancer
The aforementioned examples focus on cell-autonomous
mechanisms of modulating of intracellular cGMP signaling
in tumorigenesis. Another intriguing paradigm recognizes
the role of cGMP signaling in intercellular communication
via the secretion of GUCY2C ligands that act in an autocrine
and paracrine fashion. The GUCY2C ligands, guanylin,
and uroguanylin, are among the most commonly lost gene
products in colorectal cancers, and this loss is conserved
between mice and humans (172–176). For example, in a
study of 300 patient tumor samples, >85% exhibited loss of
guanylin (the colonic hormone) mRNA and protein expression
compared to matched normal adjacent tissue (176). Ligand
loss is also observed in the context of diet-induced obesity
and intestinal inflammation, conditions which predispose to
the development of colorectal cancer, and may represent a
mechanistic link between these risk factors and tumorigenesis
(122, 177, 178). Elimination of guanylin from mice results in loss
of epithelial cGMP, producing crypt hyperplasia (80), and ligand
reconstitution through oral administration or by transgenic
expression opposes tumorigenesis (174, 177). Importantly, the
receptor, GUCY2C, is retained in transformed tissue, despite
the loss of its ligands (16, 171, 174, 179). Collectively, these
findings underlie the paracrine hormone hypothesis of colorectal
cancer (180), which suggests that guanylin insufficiency
silences the tumor suppressive properties of the GUCY2C-
cGMP axis, producing a microenvironment conducive to
transformation.
Colorectal Cancer Prevention by Restoring
the cGMP Axis
Activation of cGMP signaling, thereby promoting epithelial
homeostasis and restoring its tumor suppressive function
represents an enticing approach to cancer prevention, potentially
overcoming irreversible genetic mutations in APC or β-
catenin. The enzymes responsible for cGMP generation and
degradation can be targeted for pharmacological regulation, for
example with GUCY2C agonists or PDE inhibitors. Among
the earliest demonstrations of the efficacy of targeting the
GUCY2C-cGMP axis for tumor prevention, Shailubhai et. al.
TABLE 2 | GUCY2C agonists shown to oppose tumorigenic cell circuits.
Structural
Analog
Functions Regulated Models
ST Ca2+ conductance, (89, 142) cell
proliferation, (85, 89) matrix
remodeling and invasion,
(156, 157) DNA damage sensing,
(113) fibroblast activation, (158)
tumor metabolism, (87) colitis and
barrier permeability, (109)
pathogen defense, (141)
carcinogen-induced
tumorigenesis, (143)
cells, mice
Guanylin matrix remodeling and invasion,
(156) colitis and barrier
permeability, (109)
obesity-induced tumorigenesis
(177)
mice
Uroguanylin Cell proliferation, (86) matrix
remodeling and invasion, (156)
polyp multiplicity (174)
mice
Linaclotide ST Polyp multiplicity, (186) cGMP
efflux, (162) intestinal pain (160)
cells, mice,
humans
Plecanatide Uroguanylin Colitis, (43) inflammation-induced
dysplasia (123)
mice
Dolcanatide Uroguanylin Colitis (43) mice
observed a reduction of tumor burden in APCmin/+ mice fed
uroguanylin in the diet (174). Since then, cGMP-elevating agents,
including PDE inhibitors (Table 1) and GUCY2C agonists
(Table 2) have been shown to oppose cellular proliferation,
genomic instability, barrier dysfunction, inflammation, dysbiosis,
desmoplasia, and other factors discussed above that contribute to
tumorigenesis.
Supporting the feasibility of targeting the cGMP axis for
tumor prevention, several cGMP elevating agents have been
shown to oppose colorectal tumorigenesis in clinical and
pre-clinical models. Early trials tested the PDE5 inhibitor,
exisulind, in patients with FAP and sporadic colorectal adenomas
(182–184). Exisulind, the sulfonated derivative of the NSAID,
sulindac, produces intracellular cGMP accumulation, driving
caspase-mediated apoptosis in cancer cells (181, 188). In
patients, exisulind treatment produced tumor cell apoptosis
and polyp regression, but significant hepatic toxicity at
therapeutic doses proved insurmountable (182–184). Further,
the antineoplastic mechanism of action has been questioned
(189), leading to interest in alternate cGMP elevating agents
with more desirable safety profiles. Recent studies have turned
to agents already FDA-approved for other disorders. These
include the PDE5 inhibitor, sildenafil, approved for the
treatment of erectile dysfunction and pulmonary hypertension
(53), and the synthetic GUCY2C ligands, plecanatide and
linaclotide, which target the secretory function of GUCY2C
to treat chronic idiopathic constipation and constipation-
predominant irritable bowel syndrome (28). Recent reports
showed that sildenafil and linaclotide administered orally in
water reduced tumor multiplicity in the APCmin/+ mouse
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(186). Furthermore, in mouse models of carcinogen-driven
(azoxymethane) and inflammation-driven (DSS) tumorigenesis,
sildenafil and plecanatide reduced the incidence of polyps
and dysplastic lesions (123, 124, 187). These promising
preclinical reports support approaching tumor prevention
through reconstitution of the silenced GUCY2C-cGMP signaling
axis.
While clinical translation of cGMP-elevating agents for
tumor prevention is a logical next step, several questions
remain to be answered regarding the mechanism of tumor
suppression by the GUCY2C-cGMP axis. One area of debate is
the nature of colorectal cancer inception, and where along the
transformation continuum cGMP exerts its effects. It remains
unclear if cGMP elevating agents oppose the initial drivers of
tumorigenesis, for example by opposing genetic instability and
therefore avoiding the sequential accumulation of mutations
beginning with APC loss. Alternatively, healthy cGMP tone
may promote a homeostatic microenvironment that suppresses
proliferative signaling, inflammation, and desmoplasia, thereby
preventing cancer progression in spite of APC/β-catenin
mutations. Another open debate is the nature of the GUCY2C-
cGMP axis suppression in cancer, and its implications for
therapeutic reconstitution of cGMP signaling. PDEs are
overexpressed in transformed tissue, albeit by an unknown
mechanism, suggesting that cGMP loss is a cell-autonomous
result of transforming mutations. In turn, PDE inhibitors
would effectively elevate epithelial cGMP and oppose tumor
progression. An alternative view recognizes that endogenous
GUCY2C ligands are suppressed early in transformation
(again, by a mechanism yet to be defined), suggesting that a
paracrine field of GUCY2C silencing is responsible for cGMP
loss and tumor susceptibility. This latter paradigm supports
the reconstitution of cGMP signaling with exogenous ligand
replacement, and forms the basis for clinical trials exploring
oral GUCY2C agonists as a chemopreventative strategy in
humans (190). The relationship between the GUCY2C-cGMP
axis and colorectal cancer inception will undoubtedly become
clearer in the coming years, and these molecular insights
will ultimately provide a mechanistic framework for tumor
prevention.
CONCLUSION
The GUCY2C-cGMP signaling axis has emerged as a key
regulator of epithelial homeostasis in the intestine. Initially
described as a the regulator of fluid and electrolyte secretion,
cGMP is now recognized for its roles in modulating epithelial
proliferation, DNA integrity, barrier function, microbiome
composition, epithelial-mesenchymal cross talk, and other
aspects of epithelial function. Dysregulation of these circuits
underlies intestinal transformation, and perhaps unsurprisingly,
loss cGMP signaling has emerged as a common feature of
colorectal tumors. The precise role of cGMP signaling in the
pathophysiology of colorectal cancer remains an open-ended
question, but its tumor-suppressive properties are diverse. As
such, suppression of cGMP signaling may be a necessary
step in tumorigenesis because it lifts a block on proliferation,
microenvironment remodeling, and the accrual of DNA
mutations necessary for transformation. Supporting this notion,
endogenous GUCY2C activating ligands are lost in early in
transformation, and also from chronically inflamed epithelium,
suggesting a mechanistic basis for this recognized risk factor
for colorectal cancer. Preclinical data from several laboratories
demonstrates that re-activation of cGMP signaling opposes
tumor formation, and the availability of FDA-approved cGMP-
elevating agents underscores the tractability of this approach.
Given these observations, the GUCY2C-cGMP axis represents a
logical, mechanism-based target for colorectal cancer prevention.
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